Atractylenolide I

Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

Product Specifications

CAS Number

[73069-13-3]

UNSPSC

12352005

Target

JAK; STAT; TNF Receptor; Toll-like Receptor (TLR)

Type

Natural Products

Related Pathways

Apoptosis; Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Atractylenolide-I.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C(C)=C(C[C@@]23[H])C(O1)=C[C@@]3(C)CCCC2=C

Molecular Formula

C15H18O2

Molecular Weight

230.30

References & Citations

[1]Atractylenolide I, et al. The JAK2/STAT3 pathway is involved in the anti-melanoma effects of atractylenolide I. Exp Dermatol. 2018 Feb;27 (2) :201-204.|[2]Gao H, et al. Anti-depressant-like effect of atractylenolide I in a mouse model of depression induced by chronic unpredictable mild stress. Exp Ther Med. 2018 Feb;15 (2) :1574-1579.|[3]Li W, et al. Atractylenolide I restores HO-1 expression and inhibits Ox-LDL-induced VSMCs proliferation, migration and inflammatory responses in vitro. Exp Cell Res. 2017 Apr 1;353 (1) :26-34.|[4]Huang JM, et al. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Sci Rep. 2014 Jan 23;4:3840.